EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Oligodendroglioma, IDH-mutant and 1p/19q-codeleted-prognostic factors, standard of care and chemotherapy, and future perspectives with neoadjuvant strategy

Hikaru Sasaki, Yohei Kitamura, Masahiro Toda, Yuichi Hirose, Kazunari Yoshida

Brain Tumor Pathology · 2024-04 · 41 (2) · 43-49

DOI: 10.1007/s10014-024-00480-1 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Brain Tumor Pathology, online erschienen am 02.04.2024. Verfasst von Hikaru Sasaki und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Tokyo Dental College Ichikawa General Hospital, 5-11-13 Sugano, Ichikawa, Chiba, 272-8523, Japan. hssasaki@tdc.ac.jp. Hauptthemen laut MEDLINE: Oligodendroglioma, Isocitrate Dehydrogenase, Brain Neoplasms, Chromosomes, Human, Pair 1. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science, Eisai.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OligodendrogliomaIsocitrate DehydrogenaseBrain NeoplasmsChromosomes, Human, Pair 1Neoadjuvant TherapyStandard of CareMutationChromosomes, Human, Pair 19HumansPrognosisAdultChromosome DeletionSurvival RateMiddle Aged

Stichwörter der Autor:innen

ChemotherapyNeoadjuvantNimustinePAVStaged resection

Substanzen

Isocitrate DehydrogenaseIDH1 protein, human

Autor:innen und Institutionen

  • Department of Neurosurgery, Tokyo Dental College Ichikawa General Hospital, 5-11-13 Sugano, Ichikawa, Chiba, 272-8523, Japan. hssasaki@tdc.ac.jp.
  • Department of Neurosurgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan. hssasaki@tdc.ac.jp.
  • Department of Neurosurgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
  • Department of Neurosurgery, Fujita Health University School of Medicine, 1-98 Dengakugakubo, Kutsukakecho, Toyoake, Aichi, 470-1192, Japan.

Förderung

  • Japan Society for the Promotion of Science
  • Eisai

Zitieren

APA

Sasaki, H., Kitamura, Y., Toda, M., Hirose, Y., & Yoshida, K. (2024). Oligodendroglioma, IDH-mutant and 1p/19q-codeleted-prognostic factors, standard of care and chemotherapy, and future perspectives with neoadjuvant strategy. Brain Tumor Pathology, 41(2), 43-49. https://doi.org/10.1007/s10014-024-00480-1

Vancouver

Sasaki H, Kitamura Y, Toda M, Hirose Y, Yoshida K. Oligodendroglioma, IDH-mutant and 1p/19q-codeleted-prognostic factors, standard of care and chemotherapy, and future perspectives with neoadjuvant strategy. Brain Tumor Pathology. 2024;41(2):43-49. doi:10.1007/s10014-024-00480-1

BibTeX
@article{Sasaki2024,
  author = {Sasaki, Hikaru and Kitamura, Yohei and Toda, Masahiro and Hirose, Yuichi and Yoshida, Kazunari},
  title = {Oligodendroglioma, IDH-mutant and 1p/19q-codeleted-prognostic factors, standard of care and chemotherapy, and future perspectives with neoadjuvant strategy},
  journal = {Brain Tumor Pathology},
  year = {2024},
  volume = {41},
  number = {2},
  pages = {43--49},
  doi = {10.1007/s10014-024-00480-1}
}
Kostenlos starten →